Enrique Grande
@drenriquegrande
Jefe del Servicio de #Oncología Médica y Director de Investigación Clínica de la Fundación MD Anderson Cancer Center Madrid. Opinions are my own
ID: 386490186
https://mdanderson.es/ 07-10-2011 11:27:25
13,13K Tweet
10,10K Followers
7,7K Following
Another historic milestone in #bladdercancer treatment delivered by Tom Powles. Last year at #ESMO23 his data displaced #chemotherapy as the standard 1L tx for metastatic disease. This year at #ESMO24 his data displaces the paradigm of #neoadjuvant chemotherapy alone by showing
Nivolumab + chemoradiotherapy in pts with MIBC #bladdercancer not undergoing cystectomy👉A phase II, randomized study by the Hellenic GU Cancer Group👉encouraging improvement in disease free- and overall survival. ESMO - Eur. Oncology #ESMO24 Congrats! OncoAlert UroToday.com Hellenic Oncological Society of Diaspora-HeL.O.DI
Great talk from Teresa Alonso Gordoa at #ESMO24 on systemic therapy for #kidneycancer key points around toxicity (see comparison across pivotal 1L studies below), innovative studies investigating novel schedules (eg TIDE-A by Roberto Iacovelli, now in European Urology), 2L therapy (w up-to-date
The most elegant way to step up to the podium at #ESMO24!!! Ramon Salazar rocking!!!! Grupo GETNE always present. Big congrats!!!!🥂🍾 Jaume Capdevila J Hernando Paula Jimenez Fonseca supporting from the first row!!!@Netespana SEOM ESMO - Eur. Oncology
Primera foto de familia del grupo de TNE y Tumores Endocrinos de Vall d’Hebron Institute of Oncology (VHIO) en #ESMO24 Muy orgulloso de trabajar con esta pequeña familia 🤩 Por muchos éxitos futuros‼️
#SunRISe-4 trial explores #TAR-200 and cetrelimab combination for #BladderCancer treatment. Andrea Necchi and Zach Klaassen discuss study results showing promising efficacy for the combination therapy and the importance of multidisciplinary care > bit.ly/4de1r6y #ESMO24
Disitamab vedotin: Promising HER2-targeted therapy for #Urothelial cancer. Matt Galsky and Zach Klaassen to discuss preliminary results from RC48G001 Study Cohort C, and the importance of HER2 and FGFR3 biomarker testing > bit.ly/3MOH1GB #ESMO24
Honored to discuss 1L urothelial treatment with the great Michiel van der Heijden. Thanks #ESMO24 OncoDaily associazionepalinuro Rebecca Johnson
Enrique Grande Honored to be one of the authors of this abstract. One important thing to raise attention to is that patients who completed all four cycles of TAR-200 achieved a 50% pCR rate! Very important to work on patients’ compliance with this therapy! Great things coming in #bladdercancer
Recién llegados de #ESMO24, ya está todo listo para el postESMO del GrupoCentroGU. El 24 de septiembre desde las 16:30h en el Eurobuilding. Ha sido un ESMO con muchas novedades, ¡no te lo pierdas! Inscripción gratuita aquí: intranet.pacifico-meetings.com/GescoWeb/?cfg=…
Loved the unique opportunity to meet & exchange ideas w friends outside of my specialty at #ESMO24 incl H. Jack West, MD, FASCO, ASCO LDP classmates leorahornmd, Neelima Denduluri & Bradley McGregor, Heather McArthur, MD, MPH, Vivek Subbiah, MD, Zhen Su, MD; MBA & so many others not pictured here! A terrific mtg & looking fwd
Identification of #BladderCancer pts that could benefit from early post-cystectomy immunotherapy based on serial circulating tumour DNA testing: Preliminary results from the #TOMBOLA trial. Presented by Jørgen Bjerggaard. #ESMO24 written coverage by Rashid K. Sayyid > bit.ly/3B40Pmy
NIAGARA shows that perioperative durvalumab plus neoadjuvant chemotherapy significantly improves event-free survival and overall survival in patients with muscle-invasive bladder cancer compared to neoadjuvant chemotherapy alone. NEJM Tom Powles #ESMO24 @oncoalert ESMO - Eur. Oncology